131 related articles for article (PubMed ID: 34699215)
1. Bradykinin-Potentiating Peptide-Paclitaxel Conjugate Directed at Ectopically Expressed Angiotensin-Converting Enzyme in Triple-Negative Breast Cancer.
Guo XM; Yadav MB; Khan M; Hao CW; Lin CY; Huang T; Wu J; Fan BM; Bian ZX
J Med Chem; 2021 Dec; 64(23):17051-17062. PubMed ID: 34699215
[TBL] [Abstract][Full Text] [Related]
2. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
3. Do the cardiovascular effects of angiotensin-converting enzyme (ACE) I involve ACE-independent mechanisms? new insights from proline-rich peptides of Bothrops jararaca.
Ianzer D; Santos RA; Etelvino GM; Xavier CH; de Almeida Santos J; Mendes EP; Machado LT; Prezoto BC; Dive V; de Camargo AC
J Pharmacol Exp Ther; 2007 Aug; 322(2):795-805. PubMed ID: 17475904
[TBL] [Abstract][Full Text] [Related]
4. A paclitaxel and microRNA-124 coloaded stepped cleavable nanosystem against triple negative breast cancer.
Chen C; Shen M; Liao H; Guo Q; Fu H; Yu J; Duan Y
J Nanobiotechnology; 2021 Feb; 19(1):55. PubMed ID: 33632232
[TBL] [Abstract][Full Text] [Related]
5. Cellular uptake mechanism and comparative evaluation of antineoplastic effects of paclitaxel-cholesterol lipid emulsion on triple-negative and non-triple-negative breast cancer cell lines.
Ye J; Xia X; Dong W; Hao H; Meng L; Yang Y; Wang R; Lyu Y; Liu Y
Int J Nanomedicine; 2016; 11():4125-40. PubMed ID: 27601899
[TBL] [Abstract][Full Text] [Related]
6. Tumor-Targeting Micelles Based on Linear-Dendritic PEG-PTX
Zhang Y; Lu Y; Zhang Y; He X; Chen Q; Liu L; Chen X; Ruan C; Sun T; Jiang C
Mol Pharm; 2017 Oct; 14(10):3409-3421. PubMed ID: 28832164
[TBL] [Abstract][Full Text] [Related]
7. RAD6 inhibition enhances paclitaxel sensitivity of triple negative breast cancer cells by aggravating mitotic spindle damage.
Haynes BM; Cunningham K; Shekhar MPV
BMC Cancer; 2022 Oct; 22(1):1073. PubMed ID: 36258187
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery.
Chen X; Plasencia C; Hou Y; Neamati N
J Med Chem; 2005 Feb; 48(4):1098-106. PubMed ID: 15715477
[TBL] [Abstract][Full Text] [Related]
9. Transcytosable Peptide-Paclitaxel Prodrug Nanoparticle for Targeted Treatment of Triple-Negative Breast Cancer.
Wang L; Zhao C; Lu L; Jiang H; Wang F; Zhang X
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36902076
[TBL] [Abstract][Full Text] [Related]
10. Improved safety and efficacy of a lipid emulsion loaded with a paclitaxel-cholesterol complex for the treatment of breast tumors.
Ye J; Liu Y; Xia X; Meng L; Dong W; Wang R; Fu Z; Liu H; Han R
Oncol Rep; 2016 Jul; 36(1):399-409. PubMed ID: 27175803
[TBL] [Abstract][Full Text] [Related]
11. Synergistic Anti-Tumor Effect of Toosendanin and Paclitaxel on Triple-Negative Breast Cancer via Regulating ADORA2A-EMT Related Signaling.
Zhang J; Xu HX; Wu YL; Cho WCS; Xian YF; Lin ZX
Adv Biol (Weinh); 2023 Aug; 7(8):e2300062. PubMed ID: 37401656
[TBL] [Abstract][Full Text] [Related]
12. A Novel Paclitaxel Derivative for Triple-Negative Breast Cancer Chemotherapy.
Liu Y; Hong G; Mao L; Su Z; Liu T; Liu H
Molecules; 2023 Apr; 28(9):. PubMed ID: 37175072
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of p300 in paclitaxel-resistant TNBC: implications for cell proliferation via the PCK1/AMPK axis.
Zhao PW; Cui JX; Wang XM
Pharmacogenomics J; 2024 Feb; 24(2):5. PubMed ID: 38378770
[TBL] [Abstract][Full Text] [Related]
14. Synergistic enhancement of apoptosis by coralyne and paclitaxel in combination on MDA-MB-231 a triple-negative breast cancer cell line.
Kumari S; Mohan MG; Shailender G; Badana AK; Malla RR
J Cell Biochem; 2019 Oct; 120(10):18104-18116. PubMed ID: 31172606
[TBL] [Abstract][Full Text] [Related]
15. Structure-function studies of BPP-BrachyNH
Arcanjo DDR; Vasconcelos AG; Nascimento LA; Mafud AC; Plácido A; Alves MMM; Delerue-Matos C; Bemquerer MP; Vale N; Gomes P; Oliveira EB; Lima FCA; Mascarenhas YP; Carvalho FAA; Simonsen U; Ramos RM; Leite JRSA
Eur J Med Chem; 2017 Oct; 139():401-411. PubMed ID: 28810191
[TBL] [Abstract][Full Text] [Related]
16. A novel EGR-1 dependent mechanism for YB-1 modulation of paclitaxel response in a triple negative breast cancer cell line.
Lasham A; Mehta SY; Fitzgerald SJ; Woolley AG; Hearn JI; Hurley DG; Ruza I; Algie M; Shelling AN; Braithwaite AW; Print CG
Int J Cancer; 2016 Sep; 139(5):1157-70. PubMed ID: 27072400
[TBL] [Abstract][Full Text] [Related]
17. Effect of Vitamin D on Paclitaxel Efficacy in Triple-negative Breast Cancer Cell Lines.
Wilhelm CA; Clor ZJ; Kelts JL
Anticancer Res; 2018 Sep; 38(9):5043-5048. PubMed ID: 30194148
[TBL] [Abstract][Full Text] [Related]
18. Design of a paclitaxel prodrug conjugate for active targeting of an enzyme upregulated in breast cancer cells.
Satsangi A; Roy SS; Satsangi RK; Vadlamudi RK; Ong JL
Mol Pharm; 2014 Jun; 11(6):1906-18. PubMed ID: 24847940
[TBL] [Abstract][Full Text] [Related]
19. circGFRA1 affects the sensitivity of triple-negative breast cancer cells to paclitaxel via the miR-361-5p/TLR4 pathway.
Zheng SR; Huang QD; Zheng ZH; Zhang ZT; Guo GL
J Biochem; 2021 Jul; 169(5):601-611. PubMed ID: 33481008
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
Liu X; Tang H; Chen J; Song C; Yang L; Liu P; Wang N; Xie X; Lin X; Xie X
Oncotarget; 2015 Aug; 6(24):20070-83. PubMed ID: 26036638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]